文献速递血栓与止血

上调cAMP可预防COVID-19中抗体介导的血栓形成

Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19.
PubMed 文献 · Blood Adv · 2022-01-01

本研究探讨COVID-19中促凝血血小板的时间进程与机制,发现患者血小板反应性IgG抗体通过FcγRIIA诱导促凝血血小板及血栓形成,而伊洛前列素(Iloprost)通过升高血小板内cAMP抑制这些事件,提示上调cAMP可能是预防COVID-19抗体介导凝血病的潜在治疗靶点。

要点

  • COVID-19患者血小板表达高水平的促凝血标志物,与血栓形成风险增加相关。
  • 血小板反应性IgG抗体通过结合FcγRIIA诱导促凝血血小板和血栓形成。
  • 伊洛前列素通过升高血小板内cAMP抑制抗体诱导的促凝血事件和血栓形成。

核心结论

  • 上调cAMP可能是预防COVID-19中抗体介导凝血病的潜在治疗靶点。

研究设计与样本

  • 本研究探究COVID-19中促凝血血小板的时间进程及机制。

主要发现

  • COVID-19患者血小板反应性IgG抗体诱导血小板线粒体内跨膜电位(Δψ)去极化增加、磷脂酰丝氨酸(PS)外化和P-选择素表达。
  • IgG诱导的促凝血血小板和血栓形成增加由血小板FcγRIIA结合介导。
  • 血小板内钙和环腺苷酸(cAMP)含量在抗体诱导的促凝血血小板形成中起核心作用。
  • 伊洛前列素抑制严重COVID-19中抗体诱导的促凝血事件及血栓形成增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thromboembolic events are frequently reported in patients infected with the SARS-CoV-2 virus. The exact mechanisms of COVID-19-associated hypercoagulopathy, however, remain elusive. Recently, we observed that platelets (PLTs) from patients with severe COVID-19 infection express high levels of procoagulant markers, which were found to be associated with increased risk for thrombosis. In the current study, we investigated the time course as well as the mechanisms leading to procoagulant PLTs in COVID-19. Our study demonstrates the presence of PLT-reactive IgG antibodies that induce marked changes in PLTs in terms of increased inner-mitochondrial transmembrane potential (Δψ) depolarization, phosphatidylserine (PS) externalization, and P-selectin expression. The IgG-induced procoagulant PLTs and increased thrombus formation were mediated by ligation of PLT Fc-γ RIIA (FcγRIIA). In addition, contents of calcium and cyclic-adenosine-monophosphate (cAMP) in PLTs were identified to play a central role in antibody-induced procoagulant PLT formation. Most importantly, antibody-induced procoagulant events, as well as increased thrombus formation in severe COVID-19, were inhibited by Iloprost, a clinically approved therapeutic agent that increases the intracellular cAMP levels in PLTs. Our data indicate that upregulation of cAMP could be a potential therapeutic target to prevent antibody-mediated coagulopathy in COVID-19 disease.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zlamal J, Althaus K, Jaffal H, et al. Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19. Blood Adv. 2022. PMID: 34753174. doi:10.1182/bloodadvances.2021005210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。